Legend Biotech Corp (LEGN) — 6-K Filings

6-K Filings (50)

• Legend Biotech Files 6-K Report — Apr 14, 2026 Risk: low
  Legend Biotech Corp. filed a Form 6-K on April 14, 2026, reporting information as a foreign issuer. The filing includes standard corporate information such as m
• 6-K Filing — Dec 8, 2025
• Legend Biotech Files 6-K with Q3 2025 Financials — Nov 12, 2025 Risk: low
  Legend Biotech Corp. filed a 6-K report on November 12, 2025, for the period ending September 30, 2025. The filing includes financial data for Q3 2025 and year-
• Legend Biotech Files 6-K Report — Nov 3, 2025 Risk: low
  Legend Biotech Corporation filed a Form 6-K on November 3, 2025, to report information as a foreign private issuer. The filing indicates that the company is sub
• Legend Biotech CARVYKTI® Sales Hit $524M — Oct 14, 2025 Risk: low
  Legend Biotech Corporation announced preliminary net sales for CARVYKTI® of approximately $524 million for the quarter ended September 30, 2025. This announceme
• Legend Biotech & Janssen Ink Supply Deal — Oct 7, 2025 Risk: low
  On October 6, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, entered into a Component and Product Supply Agreement with Janssen Phar
• Legend Biotech Files 6-K, Confirms 20-F Reporting — Aug 18, 2025 Risk: low
  Legend Biotech Corporation filed a Form 6-K on August 18, 2025. This report is for a foreign private issuer and indicates that the company files its annual repo
• Legend Biotech Files 6-K with Q2 2025 Financials — Aug 11, 2025 Risk: low
  Legend Biotech Corp. filed a 6-K report on August 11, 2025, for the period ending June 30, 2025. The filing includes financial data for the second quarter of 20
• Legend Biotech CARVYKTI® Sales Hit $439M in Q2 2025 — Jul 16, 2025 Risk: medium
  Legend Biotech Corporation announced on July 16, 2025, that its drug CARVYKTI® generated approximately $439 million in net trade sales for the quarter ended Jun
• Legend Biotech CAR T Therapies REMS Removed by FDA — Jun 30, 2025 Risk: low
  On June 26, 2025, Legend Biotech Corporation announced that the U.S. Food and Drug Administration (FDA) removed Risk Evaluation and Mitigation Strategies (REMS)
• Legend Biotech Files 2025 Annual Meeting Voting Results — Jun 12, 2025 Risk: low
  Legend Biotech Corporation held its 2025 Annual General Meeting of Shareholders on June 12, 2025. The voting results from this meeting have been filed with the
• Legend Biotech Updates Corporate Presentation — Jun 6, 2025 Risk: low
  On June 6, 2025, Legend Biotech Corporation announced it will make its updated corporate presentation available on its website and attached to this Form 6-K fil
• Legend Biotech Appoints Yale's Peter Salovey Lead Independent Director — Jun 5, 2025 Risk: low
  Legend Biotech Corporation announced on June 5, 2025, the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, as Lead Independent Direct
• Legend Biotech Files 6-K Report — Jun 3, 2025 Risk: low
  Legend Biotech Corporation filed a Form 6-K on June 3, 2025, reporting as a foreign private issuer. The company is incorporated in E9 and has its principal exec
• Legend Biotech Files 6-K Report — May 23, 2025 Risk: low
  Legend Biotech Corp. filed a Form 6-K on May 23, 2025, reporting for the month ending May 22, 2025. The filing indicates the company is a foreign private issuer
• Legend Biotech Leases New HQ in Bridgewater, NJ — May 14, 2025 Risk: low
  On May 9, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, signed an Office Lease Agreement with Legacy Bridgewater LLC. The agreement
• Legend Biotech Files Q1 2025 6-K with Financial Data — May 13, 2025 Risk: low
  Legend Biotech Corp. filed a 6-K report on May 13, 2025, for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025
• Legend Biotech Sets Annual Shareholder Meeting for June 12 — May 12, 2025 Risk: low
  Legend Biotech Corporation announced its Annual General Meeting of Shareholders will be held on June 12, 2025, at 9:00 a.m. local time at their Somerset, NJ off
• Legend Biotech CARVYKTI® Sales Hit $369M — Apr 15, 2025 Risk: low
  Legend Biotech Corporation announced on April 15, 2025, that its CARVYKTI® drug generated approximately $369 million in net trade sales for the quarter ended Ma
• Legend Biotech Files 6-K Report — Mar 11, 2025 Risk: low
  Legend Biotech Corp filed a Form 6-K on March 11, 2025, reporting its status as a foreign private issuer. The company, incorporated in E9 with its principal exe
• Legend Biotech CARVYKTI Sales Hit $334M — Jan 22, 2025 Risk: low
  Legend Biotech Corporation announced on January 22, 2025, that its drug CARVYKTI® generated approximately $334 million in net trade sales for the quarter ended
• Legend Biotech Updates Presentation for J.P. Morgan Conference — Jan 14, 2025 Risk: low
  Legend Biotech Corporation announced on January 14, 2025, that it will make an updated corporate presentation available on its website. This presentation will b
• Legend Biotech CFO Resigns Effective Jan 2, 2025 — Dec 23, 2024 Risk: medium
  Legend Biotech Corporation announced on December 18, 2024, that its Chief Financial Officer, Lori Macomber, will resign effective January 2, 2025, for personal
• Legend Biotech Files 6-K Reporting Status — Dec 10, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on December 9, 2024, reporting its status as a foreign private issuer. The company, incorporated in E9 with its prin
• Legend Biotech Files 6-K with Q3 2024 Financial Updates — Nov 12, 2024 Risk: low
  Legend Biotech Corp filed a 6-K report on November 12, 2024, for the period ending September 30, 2024. The filing includes financial data for the third quarter
• Legend Biotech Files Routine 6-K Report — Nov 5, 2024 Risk: low
  Legend Biotech Corp. filed a Form 6-K on November 5, 2024, reporting its status as a foreign private issuer. The company, incorporated in E9 with its principal
• Legend Biotech AGM Disrupted by Power Outage — Oct 22, 2024 Risk: medium
  Legend Biotech Corporation announced on October 22, 2024, that the 2024 Annual General Meeting of Shareholders was unable to cast the majority of votes due to a
• Legend Biotech Holds 2024 Shareholder Meeting — Oct 21, 2024 Risk: low
  On October 21, 2024, Legend Biotech Corporation held its 2024 Annual General Meeting of Shareholders. The voting results from this meeting have been filed with
• Legend Biotech CARVYKTI® Sales Hit $286M — Oct 15, 2024 Risk: low
  Legend Biotech Corporation announced on October 15, 2024, that CARVYKTI® generated approximately $286 million in net trade sales for the quarter ended September
• Legend Biotech Files 6-K, Confirms 20-F Reporting — Sep 27, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on September 27, 2024, to report its status as a foreign private issuer. The company, incorporated in E9 with its pr
• Legend Biotech Sets Shareholder Meeting for Oct 21 — Sep 20, 2024 Risk: low
  Legend Biotech Corporation announced on September 20, 2024, that its Annual General Meeting of Shareholders will be held on October 21, 2024, at 9:30 a.m. local
• Legend Biotech's Cilta-cel Approved in China for Multiple Myeloma — Aug 27, 2024 Risk: medium
  On August 27, 2024, Legend Biotech Corporation announced that China's National Medical Products Administration (NMPA) approved their New Drug Application for ci
• Legend Biotech Files 6-K for Q2 2024 — Aug 9, 2024 Risk: low
  Legend Biotech Corp. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data and details related to its operations. Specific
• Legend Biotech Files 6-K Report — Aug 8, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on August 8, 2024, to report information as a foreign private issuer. The filing indicates the company is submitting
• Legend Biotech Files Routine 6-K Disclosure — Jul 26, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on July 26, 2024, to report its status as a foreign private issuer filing annual reports under Form 20-F. The filing
• Legend Biotech CARVYKTI Sales Hit $186M — Jul 17, 2024 Risk: low
  Legend Biotech Corporation announced on July 17, 2024, that its drug CARVYKTI® generated approximately $186 million in net trade sales for the quarter ended Jun
• Legend Biotech Files 6-K, Confirms 20-F Reporting — Jul 2, 2024 Risk: low
  Legend Biotech Corp. filed a Form 6-K on July 2, 2024, reporting as a foreign private issuer. The filing indicates the company will file its annual reports unde
• Legend Biotech Presents CARVYKTI Data at ASCO and EHA — Jun 3, 2024 Risk: low
  Legend Biotech Corporation announced on June 3, 2024, new data from its Phase 2 CARTITUDE-2 Cohort D study. The study focused on multiple myeloma patients who h
• Legend Biotech to Present CARVYKTI Data at ASCO and EHA — May 23, 2024 Risk: low
  Legend Biotech Corporation announced on May 23, 2024, that new and updated clinical data for its CAR-T cell therapy, CARVYKTI® (ciltacabtagene autoleucel), will
• Legend Biotech Files 6-K for Q1 2024 — May 13, 2024 Risk: low
  Legend Biotech Corp filed a 6-K report for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and the full year
• European Commission Approves Legend Biotech's CARVYKTI for 2nd-Line MM — Apr 22, 2024 Risk: low
  On April 22, 2024, Legend Biotech Corporation announced that the European Commission (EC) has approved CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the
• Legend Biotech Files 6-K Report — Apr 16, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on April 16, 2024, to report preliminary information. The filing indicates the company is a foreign private issuer a
• FDA Approves Legend Biotech's CARVYKTI for Multiple Myeloma — Apr 8, 2024 Risk: low
  On April 5, 2024, Legend Biotech Corporation announced that the U.S. FDA approved CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with
• Legend Biotech Signs Master Services Agreement with Novartis — Mar 29, 2024 Risk: medium
  Legend Biotech Corporation filed a Form 6-K on March 29, 2024, reporting its entry into a Master Services Agreement with Novartis. The filing does not specify d
• Legend Biotech Files 6-K, Mentions FDA Advisory Committee — Mar 15, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on March 15, 2024, reporting its status as a foreign private issuer. The filing indicates the company is subject to
• Legend Biotech Files 6-K on FDA Briefing Books — Mar 13, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on March 13, 2024, reporting on the release of Sponsor and FDA Briefing Books. The company, incorporated in E9 with
• Legend Biotech Files 6-K for Q4 2023 Results — Mar 11, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K on March 11, 2024, reporting its fourth quarter and full year 2023 results. The filing indicates the company's princ
• Legend Biotech Files 6-K as Foreign Private Issuer — Feb 23, 2024 Risk: low
  Legend Biotech Corporation filed a Form 6-K with the SEC on February 23, 2024, indicating it is a foreign private issuer. The filing confirms the company's addr
• Legend Biotech: CARVYKTI® Q4 Preliminary Sales Hit $159M — Jan 23, 2024
  Legend Biotech Corp. announced on January 23, 2024, that its multiple myeloma drug, CARVYKTI®, generated approximately $159 million in preliminary net trade sal
• Legend Biotech Updates Corporate Presentation for J.P. Morgan Conference — Jan 9, 2024
  Legend Biotech Corporation filed a 6-K on January 9, 2024, to announce it will make its updated corporate presentation available on its website. This presentati

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX